Tecan's Financial Performance in H1 2024
Tecan reported financial results for the first half of 2024, reflecting a challenging market environment. Sales dropped to CHF 467.2 million, a decline of 13.7% in Swiss francs. This decrease is primarily due to reduced demand in biopharmaceutical instruments and market weakness in China. The company is seeing a return to pre-pandemic seasonality, expecting stronger sales in the second half of the year.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
